ABBV-951, an innovative investigational drug developed by AbbVie, offers hope for patients with advanced Parkinson's disease by providing continuous subcutaneous delivery of carbidopa and levodopa prodrugs, aiming to address motor fluctuations more effectively than oral medication.
Leveraging its small molecule design and targeted action on dopamine receptors, ABBV-951 presents a promising approach to managing the challenging symptoms of Parkinson's disease, including tremors, muscle rigidity, and impaired movement, offering potential improvements in patients' quality of life.
Parkinson's disease (PD) poses significant challenges as it progresses, with motor f...
